Works matching DE "IMMUNE checkpoint inhibitors"

Results: 5000

Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact.

Published in:

CTS: Clinical & Translational Science, 2025, v. 18, n. 5, p. 1, doi. 10.1111/cts.70221

By:

Yu, Tian;
Wu, Chi‐Yuan;
Sahasranaman, Srikumar;
Tian, Xianbin;
Fei Li, Ying;
Tang, Zhiyu;
Yang, Yanfei;
Wan, Ya;
Zhang, Quting;
Schnell, Patrick;
Mendoza‐Naranjo, Ariadna;
Abdrashitov, Ramil;
Hanley, William D.;
Budha, Nageshwar

Publication type:

Article

Combined stereotactic radiation therapy and immunotherapy for metastatic uveal melanoma.

Published in:

Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2025.1567504

By:

Nazarova, Valeria V.;
Orlova, Kristina V.;
Magomedova, Zakhra R.;
Romanov, Denis S.;
Maskalenka, Raman;
Yarovoy, Andrey A.;
Yarovaya, Vera A.;
Trofimova, Oxana P.;
Shubina, Irina Zh.;
Demidov, Lev V.

Publication type:

Article

Consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology on the management of muscle-invasive and advanced urothelial carcinoma.

Published in:

Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2025.1564487

By:

Poon, Darren M.C.;
Chiu, Peter K.F.;
Chan, Marco T.Y.;
Ho, Brian S.H.;
Law, K.S.;
Leung, Angus K.C.;
Leung, Clarence L.H.;
Na, R.;
Wong, Kenneth C.W.;
Wu, Philip Y.;
Kwong, Philip W.K.;
Teoh, Jeremy Y.C.

Publication type:

Article

Pathologic complete response after Sintilimab combined with FOLFOX therapy in MSI-H type patients with locally advanced GC: a case report.

Published in:

Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2025.1560450

By:

Wang, Xiaoke;
Gu, Yuanhui;
Yi, Lin;
Wu, Tao;
Wang, Ling;
Tian, Jiao;
Lu, Yuyuan;
Jin, Penghui;
Yang, Xin;
Yang, Yan

Publication type:

Article

Gut microbes and immunotherapy for non-small cell lung cancer: a systematic review.

Published in:

Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2025.1518474

By:

Jin, Yali;
Jie, Zhiqian;
Fan, Xianming

Publication type:

Article

Editorial: Exploring macrophage roles in cancer progression and therapeutic targeting.

Published in:

Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2025.1612588

By:

Karagiannis, George S.;
Kato, Yu;
Entenberg, David

Publication type:

Article

Multi-omics analysis and experiments uncover the link between cancer intrinsic drivers, stemness, and immunotherapy in ovarian cancer with validation in a pan-cancer census.

Published in:

Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2025.1549656

By:

Li, Yilin;
Chen, Cen;
Ji, Xiaoyu;
Jiang, Ningxiao;
Wang, Fei;
Gao, Xiangqian;
Chen, Weiwei;
Tang, Qiang;
Li, Yan;
Zhang, Shinan;
Qin, Gaofeng;
Xu, Yingjiang;
Wang, Yanlin;
Kong, Lingwen;
Han, Lei;
Mei, Jie

Publication type:

Article

Development and validation of an ARID1A-related immune genes risk model in evaluating prognosis and immune therapeutic efficacy for gastric cancer patients: a translational study.

Published in:

Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2025.1541491

By:

Zhang, Jiangtao;
Li, Jingting;
Yang, Shangfeng;
Tang, Xiaoyan;
Wang, Chunze;
Lin, Jiaxing;
Chen, Qiancheng;
Xu, Hui;
Ma, Yuanyuan;
Gao, Xiaoling

Publication type:

Article

Integrative single-cell and spatial transcriptomics analysis reveals MDK-NCL pathway's role in shaping the immunosuppressive environment of lung adenocarcinoma.

Published in:

Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2025.1546382

By:

Fu, Yu;
Li, Song;
Zhao, Yikang;
Zhang, Xiran;
Mao, Xiaolu;
Xu, Ran

Publication type:

Article

Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma.

Published in:

Journal of Gastroenterology, 2025, v. 60, n. 6, p. 770, doi. 10.1007/s00535-025-02239-7

By:

Oura, Kyoko;
Morishita, Asahiro;
Yano, Rie;
Manabe, Takushi;
Takuma, Kei;
Nakahara, Mai;
Tadokoro, Tomoko;
Fujita, Koji;
Mimura, Shima;
Tani, Joji;
Tatsuta, Miwa;
Himoto, Takashi;
Masaki, Tsutomu;
Kobara, Hideki

Publication type:

Article

Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.

Published in:

Journal of Gastroenterology, 2025, v. 60, n. 6, p. 738, doi. 10.1007/s00535-025-02233-z

By:

Aoki, Tomoko;
Kudo, Masatoshi;
Nishida, Naoshi;
Ueshima, Kazuomi;
Tsuchiya, Kaoru;
Tada, Toshifumi;
Morita, Masahiro;
Chishina, Hirokazu;
Takita, Masahiro;
Hagiwara, Satoru;
Ida, Hiroshi;
Minami, Yasunori;
Kuroda, Hidekatsu;
Nakamura, Noriaki;
Hiraoka, Atsushi;
Tomonari, Tetsu;
Tani, Joji;
Naganuma, Atsushi;
Kakizaki, Satoru;
Ogawa, Chikara

Publication type:

Article

The emerging role of lymphocyte‐activation gene 3 targeting in the treatment of solid malignancies.

Published in:

Cancer (0008543X), 2025, v. 131, n. 10, p. 1, doi. 10.1002/cncr.35892

By:

Giri, Vinay K.;
McDermott, David F.;
Zaemes, Jacob

Publication type:

Article

FDA Approves Retifanlimab-Dlwr With Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal.

Published in:: ONS Voice, 2025, p. N.PAG
Publication type:: Article

Κολίτιδα οφειλόμενη στην ανοσοθεραπεία.

Published in:

Nosileftiki, 2025, v. 65, n. 1, p. 21

By:

Τσαγκάνης, Γεώργιος;
Παπαγεωργίου, Δημήτριος;
Γκοβίνα, Ουρανία;
Καλεμικεράκης, Ιωάννης

Publication type:

Article

Neutrophil/lymphocyte ratio: a potential biomarker in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.

Published in:

Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2025.1557652

By:

Caterino, Marianna;
Lo Giudice, Giorgio;
Damiano, Vincenzo;
Perri, Francesco;
Giordano, Guido;
Ciardiello, Davide;
Mirabile, Aurora;
Pirozzi, Mario;
Sponghini, Andrea Pietro;
Ricci, Vincenzo;
Montella, Liliana;
Addeo, Raffaele;
Vignani, Francesca;
Famiglietti, Vincenzo;
Farese, Stefano;
Di Lorenzo, Sara;
Ciardiello, Fortunato;
Fasano, Morena

Publication type:

Article

Ovarian cancer targeted therapy: current landscape and future challenges.

Published in:

Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2025.1535235

By:

Wang, Guangli;
Yang, Hui;
Wang, Yuling;
Qin, Juan

Publication type:

Article

Pembrolizumab‐Associated Multiorgan Sarcoid‐Like Reaction: A Case Report and Review of Literature.

Published in:

Case Reports in Medicine, 2025, v. 2025, p. 1, doi. 10.1155/carm/9915002

By:

Enayah, Majd;
Al-Aqtash, Tameem;
Mégarbane, Bruno

Publication type:

Article

A Novel Hypoxia-Featured Genes Prognostic Model for Identification of Hypoxia Subtypes in Diffuse Large B-Cell Lymphoma.

Published in:

Cell Biochemistry & Biophysics, 2025, v. 83, n. 2, p. 2265, doi. 10.1007/s12013-024-01637-7

By:

LYU, Geng;
Sun, Ruixin;
Liu, Xiaxin;
Xu, Zizhen

Publication type:

Article

Co-Occurrence of Hypophysitis and Thyroiditis Induced by PD-L1 Inhibitor Avelumab: Clinical Insights Open Access.

Published in:

2025

By:

Zavgorodneva, Zhanna;
Khan, Muzammil;
Guber, Helena

Publication type:

Case Study

An Extremely Rare Case of Immune Checkpoint Inhibitors–Related Hypoparathyroidism and a Critical Literature Review Open Access.

Published in:

JCEM Case Reports, 2025, v. 3, n. 6, p. 1, doi. 10.1210/jcemcr/luaf097

By:

Kazanas, Spyridon;
Anastasopoulou, Amalia;
Ziogas, Dimitrios;
Gogas, Helen;
Angelousi, Anna

Publication type:

Article

First-line treatment patterns and overall survival in patients diagnosed with metastatic Merkel cell carcinoma in England from 2013 to 2020: results of a nationwide observational cohort study Open Access.

Published in:

British Journal of Dermatology, 2025, v. 192, n. 6, p. 1134, doi. 10.1093/bjd/ljaf063

By:

Mahmoudpour, Seyed Hamidreza;
Knott, Craig;
Nobes, Jenny;
Kearney, Mairead;
Boutmy, Emmanuelle;
Verpillat, Patrice;
Venables, Zoe C

Publication type:

Article

Tumor-associated MerTK promotes a pro-inflammatory microenvironment and enhances immune checkpoint inhibitor response in triple-negative breast cancer.

Published in:

Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2025.1579214

By:

Crossman, Bridget E.;
Harmon, Regan L.;
Iida, Mari;
Adams, Jillian M.;
Lin, Candie Y.;
Glitchev, Christine E.;
Juang, Terry D.;
Kerr, Sheena C.;
Alexandridis, Roxana A.;
Hyun, Meredith;
Yang, David T.;
Kang, Irene;
Salgia, Ravi;
Wheeler, Deric L.

Publication type:

Article

Itolizumab regulates activating and inhibitory signals on effector cells, improving their cytotoxicity against CD318+ tumor cell lines.

Published in:

Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2025.1585597

By:

González Muñoz, Cynthia;
Álvarez Arzola, Rydell;
Calvo Pérez, Adanays;
Frometa Campanón, Milagro de la Caridad;
Hernández Casaña, Patricia;
Fernández-Calienes Valdés, Aymé;
Lorenzo-Luaces, Patricia;
Mazorra Herrera, Zaima;
Crombet Ramos, Tania;
Labrada Mon, Mayrel

Publication type:

Article

Therapeutic options for human papillomavirus‐positive tonsil and base of tongue cancer.

Published in:

Journal of Internal Medicine, 2025, v. 297, n. 6, p. 608, doi. 10.1111/joim.20088

By:

Zupancic, Mark;
Kostopoulou, Ourania N.;
Marklund, Linda;
Dalianis, Tina

Publication type:

Article

Minimum requirements for the introduction of immuno-oncology medicines in low-and lower middle-income countries.

Published in:

International Journal of Healthcare Management, 2025, v. 18, n. 2, p. 205, doi. 10.1080/20479700.2023.2284464

By:

Adeyemo, Tosin;
Wilsdon, Tim;
Hartevelt, Michael;
Kalappura, Jobin Joseph;
Roediger, Alexander;
Vink, Sjaak;
Roane, Tom;
Rasool, Yusuf;
Whitehill, Robert;
Tung, Patrick;
Cordebel, Augusto Cesar;
Robson, Lee;
Hjulsager, Morten;
Korte, Miguel

Publication type:

Article

Baseline Inflammatory Burden Index Predicts Primary Resistance to Combinations of ICIs With Chemotherapy in Patients With HER-2-Negative Advanced Gastric Cancer.

Published in:

Journal of Gastric Cancer, 2025, v. 25, n. 2, p. 266, doi. 10.5230/jgc.2025.25.e14

By:

Tingting Wang;
Huihui Zeng;
Ting Hu;
Junhao Zhang;
Zishu Wang

Publication type:

Article

Integrating antigen capturing nanoparticles and type 1 conventional dendritic cell therapy for in situ cancer immunization.

Published in:

Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-025-59840-w

By:

Chao, Chih-Jia;
Zhang, Endong;
Trinh, Duong N.;
Udofa, Edidiong;
Lin, Hanchen;
Silvers, Caylee;
Huo, Jiawei;
He, Shan;
Zheng, Jingtian;
Cai, Xiaoying;
Bao, Qing;
Zhang, Luyu;
Phan, Philana;
Elgendy, Sara M.;
Shi, Xiangqian;
Burdette, Joanna E.;
Lee, Steve Seung-Young;
Gao, Yu;
Zhang, Peng;
Zhao, Zongmin

Publication type:

Article

The current status and prospects of gut microbiota combined with PD-1/PD-L1 inhibitors in the treatment of colorectal cancer: a review.

Published in:

BMC Gastroenterology, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12876-025-03968-y

By:

Deng, Min;
Li, Xiaoyu;
Wu, Huiming;
Xue, Dingwen;
Wang, Yize;
Guo, Renkai;
Cui, Yipeng;
Jin, Chenfei;
luo, Fei;
Li, Huiyu

Publication type:

Article

PD‐L1, PD‐1, and CTLA‐4 mRNA In Situ Expression by Canine Oral Melanoma Cells and Immune Cells of the Tumour Microenvironment.

Published in:

Veterinary & Comparative Oncology, 2025, v. 23, n. 2, p. 141, doi. 10.1111/vco.13039

By:

Foiani, Greta;
Melchiotti, Erica;
Capello, Katia;
Porcellato, Ilaria;
Brachelente, Chiara;
Iussich, Selina;
Giacobino, Davide;
Morello, Emanuela;
Martano, Marina;
Buracco, Paolo;
Vascellari, Marta

Publication type:

Article

An update on the clinical trial research of immunotherapy for glioblastoma.

Published in:

Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2025.1582296

By:

Zhou, Yichen;
Shi, Fanxing;
Zhu, Junyu;
Yuan, Yi

Publication type:

Article

First-line immune checkpoint inhibitors with chemotherapy in advanced gastric and gastroesophageal junction adenocarcinoma: a meta-analysis of phase 3 trials.

Published in:

Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2025.1564604

By:

Lin, Yuxuan;
Liao, Yonghe;
Shen, Jinhai

Publication type:

Article

The association of immune-inflammation indices at multiple time points with treatment response and survival in advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors.

Published in:

World Journal of Surgical Oncology, 2025, v. 23, n. 1, p. 1, doi. 10.1186/s12957-025-03833-y

By:

Li, Yaqing;
Xu, Jianping;
Zhang, Lijuan;
Cai, Zhigang

Publication type:

Article

Single-cell transcriptomic analysis deciphers the inflammatory microenvironment characterized by CXCL9+ fibroblasts and ACKR1+ endothelial cells in immune-related myocarditis.

Published in:

Journal of Translational Medicine, 2025, v. 23, n. 1, p. 1, doi. 10.1186/s12967-025-06551-x

By:

Sun, Boyu;
Xun, Ziyu;
Zhou, Zixiang;
Zhang, Nan;
Piao, Mingjian;
Li, Chengjie;
Li, Jiongyuan;
Li, Shuofeng;
Zhang, Longhao;
Chen, Xiangqi;
Wang, Hanping;
Zhao, Haitao

Publication type:

Article

局部晚期宫颈癌免疫治疗进展.

Published in:

Practical Oncology Journal, 2025, v. 39, n. 2, p. 157, doi. 10.11904/j.issn.1002-3070.2025.02.012

By:

王孟菲;
综述;
许波群;
审校

Publication type:

Article

Discussion on the application of sweet-natured herbs to the treatment of tumor immune-related adverse events based on the theory of "fire and primordial qi incompatibility".

Published in:

Journal of Beijing University of Traditional Chinese Medicine, 2025, v. 48, n. 4, p. 1, doi. 10.3969/j.issn.1006-2157.2025.04.015

By:

Jiahe, WU;
Muyao, CUI;
Weidong, LI

Publication type:

Article

がん免疫と腸内細菌叢－常在ビフィズス菌の役割－.

Published in:

Nishinihon Journal of Urology, 2025, v. 87, n. 4, p. 227

By:

末金茂高;
植田浩介;
伊東直城;
井川掌

Publication type:

Article

根治切除不能な局所進行性および転移性尿路上皮癌 (la/mUC) における新規一次治療の選択肢.

Published in:

Nishinihon Journal of Urology, 2025, v. 87, n. 4, p. 190

By:

鑪野秀一;
榎田英樹

Publication type:

Article

-筋層浸潤性膀胱癌 (MIBC) の治療戦略 - RARC と周術期薬物療法の現状と展望.

Published in:

Nishinihon Journal of Urology, 2025, v. 87, n. 4, p. 188

By:

木村隆;
猪口淳一

Publication type:

Article

Phase II Study of Short Hydration without Diuretics for Cisplatin-Based Chemotherapy.

Published in:

Journal of Nippon Medical School, 2025, v. 92, n. 2, p. 188, doi. 10.1272/jnms.JNMS.2025_92-210

By:

Tetsuya Wako;
Ryosuke Arakawa;
Shinji Nakamichi;
Masaru Matsumoto;
Rei Yamaguchi;
Kaoruko Shimbu;
Tomoyasu Inoue;
Takehiro Tozuka;
Junichi Aoyama;
Yasuhiro Kato;
Naomi Onda;
Akihiko Miyanaga;
Masahiro Seike;
Kaoru Kubota

Publication type:

Article

A novel model for predicting immunotherapy response and prognosis in NSCLC patients.

Published in:

Cancer Cell International, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12935-025-03800-3

By:

Zang, Ting;
Luo, Xiaorong;
Mo, Yangyu;
Lin, Jietao;
Lu, Weiguo;
Li, Zhiling;
Zhou, Yingchun;
Chen, Shulin

Publication type:

Article

Development and validation of a nomogram model for predicting immune-mediated hepatitis in cancer patients treated with immune checkpoint inhibitors.

Published in:

BioScience Trends, 2025, v. 19, n. 2, p. 202, doi. 10.5582/bst.2024.01351

By:

Qianjie Xu;
Xiaosheng Li;
Yuliang Yuan;
Zuhai Hu;
Wei Zhang;
Ying Wang;
Ai Shen;
Haike Lei

Publication type:

Article

Comparative efficacy of interventional therapy with or without targeted immunotherapy in Child-Pugh B hepatocellular carcinoma patients: a single-center, retrospective study.

Published in:

Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2025.1541805

By:

Guo, Xu-Wei;
Zhao, Man;
Duan, Xiao-Ling;
Han, Guang-Jie;
Wang, Jin-Feng;
Shi, Jian-Fei;
Han, Xin;
Yin, Fei;
Yang, Guang

Publication type:

Article

Rewiring lipid metabolism to enhance immunotherapy efficacy in melanoma: a frontier in cancer treatment.

Published in:

Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2025.1519592

By:

Xiong, Lihua;
Cheng, Jian

Publication type:

Article

Metabolic reprogramming and immune microenvironment characteristics in laryngeal carcinoma: advances in immunotherapy.

Published in:

Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2025.1589243

By:

Ma, Kexin;
Mao, Qingjie;
Fei, Bing;
Ni, Tingting;
Zhang, Zhenxin;
Ni, Haosheng

Publication type:

Article

Case Report: Combined PD-1 and tyrosine kinase blockade stabilizes refractory pancreatic cancer guided by the spatial structure of tumor immune microenvironment.

Published in:

2025

By:

Yang, Heqi;
Ma, Yuhang;
Zhang, Chenyan;
Leng, Qingqing;
Cheng, Ke;
Zhao, Chengjian;
Cao, Dan

Publication type:

Case Study

Nivolumab in Relapsed or Refractory Primary Central Nervous System Lymphoma: Multicenter, Retrospective Study.

Published in:

Cancer Research & Treatment, 2025, v. 57, n. 2, p. 590, doi. 10.4143/crt.2024.531

By:

Yi, Jun Ho;
Kim, Seok Jin;
Kim, Sang-A;
Jung, Jongheon;
Yoon, Dok Hyun

Publication type:

Article

Unraveling the Impact of Sarcopenia-Induced Lymphopenia on Treatment Response and Prognosis in Patients with Stage III Non–Small Cell Lung Cancer: Insights for Optimizing Chemoradiation and Immune Checkpoint Inhibitor.

Published in:

Cancer Research & Treatment, 2025, v. 57, n. 2, p. 422, doi. 10.4143/crt.2024.493

By:

Lee, Joongyo;
Kim, Kyung Hwan;
Kim, Jina;
Lee, Chang Geol;
Cho, Jaeho;
Yoon, Hong In;
Cho, Yeona

Publication type:

Article

Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial.

Published in:

International Journal of Cancer, 2025, v. 157, n. 2, p. 336, doi. 10.1002/ijc.35407

By:

Gao, Yuan;
Cheng, Ann‐Lii;
Li, Lee X.;
Parent, Natalie;
Kichenadasse, Ganessan;
Karapetis, Christos S.;
Rowland, Andrew;
Hopkins, Ashley M.;
Sorich, Michael J.

Publication type:

Article

Eosinophil‐induced adverse events induced by treatment with programmed cell death 1/ligand 1 inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system.

Published in:

International Journal of Cancer, 2025, v. 157, n. 2, p. 317, doi. 10.1002/ijc.35398

By:

Lyu, Lu;
Bian, Sainan;
Guan, Kai;
Zhao, Bin

Publication type:

Article

Successful treatment of localized scleroderma using brodalumab: A case report.

Published in:

2025

By:

Bobica, Alexandra Carla;
Zhu, Catherine;
Silotch, Catherine;
BinJadeed, Hessah;
Netchiporouk, Elena

Publication type:

Case Study